Zentalis Pharmaceuticals, Inc.SEC Filings
|
|
All SEC filings by Zentalis Pharmaceuticals, Inc. (ZNTL) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| 10-Q | Quarterly report | View Diff | May 12, 2026 | |
| ARS | Annual report to shareholders | Apr 30, 2026 | ||
| 10-K | Annual report | View Diff | Mar 26, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 10, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 6, 2025 | |
| 10-Q | Quarterly report | View Diff | May 14, 2025 | |
| ARS | Annual report to shareholders | Apr 30, 2025 | ||
| 10-K | Annual report | View Diff | Mar 26, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 12, 2024 |
Events
| 8-K | Current report | Aug 14, 2026 | ||
| 8-K | Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates | Aug 6, 2026 | ||
| 8-K | Current report | Jun 18, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | May 27, 2026 | ||
| 8-K | Regulation Fd Disclosure | May 21, 2026 | ||
| 8-K | Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress | May 12, 2026 | ||
| 8-K | Regulation Fd Disclosure | May 5, 2026 | ||
| 8-K | Regulation Fd Disclosure | Apr 17, 2026 | ||
| 8-K | Regulation Fd Disclosure | Apr 9, 2026 | ||
| 8-K | Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates | Mar 26, 2026 |
Registrations and Prospectuses
| 424B5 | Prospectus supplement for primary offering | Aug 14, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | Aug 13, 2026 | ||
| S-8 | Registration of securities for employees | May 14, 2025 | ||
| S-3 | Shelf registration | Mar 26, 2025 | ||
| S-8 | Registration of securities for employees | Feb 29, 2024 | ||
| S-3ASR | Automatic shelf registration | Feb 29, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Jun 15, 2023 | ||
| FWP | Free writing prospectus | Jun 15, 2023 | ||
| S-8 | Registration of securities for employees | Aug 9, 2022 | ||
| 424B5 | Prospectus supplement for primary offering | May 16, 2022 |
Proxies
| DEFA14A | Annual Meeting of Shareholders | May 27, 2026 | ||
| DEFA14A | Proxy Filing | Apr 30, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Apr 30, 2026 | |
| DEFA14A | Additional proxy soliciting materials | May 23, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 30, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 30, 2025 | |
| DEFA14A | Additional proxy soliciting materials | May 29, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2024 | |
| DEFA14A | Additional proxy soliciting materials | May 10, 2023 |
Other
| EFFECT | Notice of effectiveness | Apr 7, 2025 | ||
| CORRESP | Correspondence with SEC | Apr 2, 2025 | ||
| UPLOAD | Letter from SEC | Apr 1, 2025 | ||
| UPLOAD | Letter from SEC | Oct 17, 2024 | ||
| CORRESP | Correspondence with SEC | Oct 10, 2024 | ||
| UPLOAD | Letter from SEC | Sep 12, 2024 | ||
| UPLOAD | Letter from SEC | Jun 29, 2022 | ||
| CORRESP | Correspondence with SEC | Jun 22, 2022 | ||
| UPLOAD | Letter from SEC | Jun 9, 2022 | ||
| CORRESP | Correspondence with SEC | May 26, 2022 |
Ownership
| 4 | Bruns Ingmar | Oct 1, 2026 | ||
| SC 13G/A | Walters Group Updates Stake in Zentalis Pharmaceuticals, Inc. | Aug 19, 2026 | ||
| 4 | Walters Group | Aug 19, 2026 | ||
| SC 13G/A | Barclays Plc Updates Stake in Zentalis Pharmaceuticals, Inc. | Aug 13, 2026 | ||
| SC 13G | Blackrock, Inc. Acquires Stake in Zentalis Pharmaceuticals, Inc. | Jul 30, 2026 | ||
| 4 | Johnson David Michael | Jun 18, 2026 | ||
| 4 | Skvarka Jan | Jun 18, 2026 | ||
| 4 | Walker Luke Nathaniel | Jun 18, 2026 | ||
| 4 | Kariuki Enoch | Jun 18, 2026 | ||
| 4 | Myers Scott Dunseth | Jun 18, 2026 |